The purpose of this curriculum is to serve as a resource for Project RAMP providers. This curriculum covers topics about opioid use disorder (OUD), how to treat and manage this condition using medication-assisted treatment (MAT), and how to implement substance use disorder (SUD) screening and MAT through Project RAMP. The curricular content is a collection of resources from experts in SUD/OUD and MAT as well as resources created by the Project RAMP Implementation Team. One may complete the entire curriculum or the sections one prefers.

Some webinars and resources with audio/video require Adobe Connect. Download Adobe Connect here.

Please view the welcome video from Dr. Adam Gordon for an introduction to the Project RAMP educational offerings: Introduction to the Project RAMP educational offerings

To begin, select the topic that you are interested in and then select the resource in the Tool or Resource column you wish to learn more about.

Please note that additional educational tools and resources are available within your course. Please use your Project RAMP log-in to access additional content on your course page. Webinars on the page can be viewed by logging in as a guest.

Section 1: Overview of Opioid Use Disorder

  1. Understanding Substance Use Disorders and Opioid Use Disorders

  2. Stigma Reduction Training

ModuleTopicSubtopicTool or Resource

Module 1 

Overview of Opioid Use Disorder (OUD)

Understanding Substance Use Disorders & Opioid Use Disorders

Neurobiology of Opioid Use Disorders

What is Opioid Use Disorder (Slides)

MAT Myths and Realities

Common Myths about Medication-Assisted Treatment (Providers / Patients)

Policy Implications of MAT

Policy Implications of MAT (Slides)

Stigma Reduction Training

Talking About Substance Use

Reducing Stigmatizing Language Surrounding Substance Use (Document)

Section 2: Essentials of Medication Assisted Treatment (MAT)

  1. MAT Essentials

    1. MAT Procedures in Primary Care
  2. MAT Pharmacology

    1. Overview
    2. Full Opioid Antagonist (Naltrexone) 
    3. Partial Opioid Agonist (Buprenorphine)
    4. Extended Release Injectable Buprenorphine 
  3. DATA 2000 Certification

    1. Waiver Instructions

ModuleTopicSubtopicTool or Resource

Module 2

Essentials of Medication Assisted Treatment (MAT)

MAT Essentials

MAT Procedures in Primary Care

Addressing Substance Use Disorder and Opioid Use Disorder in Family Medicine and Primary Care (Slides)

What is Necessary and Sufficient to Provide Naltrexone or Buprenorphine in Primary Care Settings? (Slides)

MAT Pharmacology


Overview of MAT Medications and the Role of Counseling (Webinar)

Full Opioid Antagonist Naltrexone 

Naltrexone for OUD (Slides)

Partial Opioid Agonist Buprenorphine 

Strategies to Successfully Complete Buprenorphine Induction (Webinar)

Office and Home Buprenorphine Induction (Slides)

Extended-Release Injectable Buprenorphine

Extended-Release Injectable Buprenorphine (Sublocade™) (Webinar)

DATA 2000 Certification

Waiver Instructions 

DATA 2000 Waiver Checklist (Document)

Section 3: Addressing and Managing Opioid Use Disorder

  1. Patient Assessment

    1. Screening
    2. Brief Intervention and Motivational Interviewing Principles
    3. Referral to Treatment: Resources in Pennsylvania
    4. SBIRT Supplementary Resources
  2. Patient Monitoring

ModuleTopicSubtopicTool or Resource

Module 3

Addressing and Managing Opioid Use Disorder

Patient Assessment 


The Importance of Screening for SUD/OUD in Primary Care (Document)

Review of AUD and OUD Screening – Assessment Approach and Tools (Slides)

Brief Intervention and Motivational Interviewing Principles

Under Development

Patient Monitoring

Urine Drug Screening

How to Correctly Interpret a Urine Drug Screen Result (Slides)

Compliance Testing and Addressing Recurring Opioid Use and Polysubstance Use (Slides/Webinar)

Section 4: Project Implementation

  1. Project RAMP Overview

    1. Core Activities
    2. Care Management Models
  2. Protocols

  3. Tools and Resources

ModuleTopicSubtopicTool or Resource

Module 4

Project Implementation

Project RAMP Overview 

Core Activities 

RAMP One Page Summary (Documents)

Project RAMP Training Summary and Timeline (Document)

Care Management Models 

Project RAMP Care Management Strategies (Slides)



General Office-Based Opioid Treatment (OBOT) Protocol (Document)

Medication-Assisted Treatment: Urine Drug Screening Guide (Document)

Tools and Resources Tools

Section 5: Managing Special Populations

  1. Adolescents and Young Adults

  2. Pregnant Women

ModuleTopicSubtopicTool or Resource

Module 5

Managing Special Populations

Adolescents and Young Adults 

Adolescent Substance Use

Prevalence of Adolescent Substance Use (Webinar)

Risk and Vulnerability (Webinar)

Screening for and Assessing Adolescent Substance Use (Webinar)

Communicating with Patients and Caregivers (Webinar)

Treating Adolescent Substance Use (Webinar)

Pregnant Women


Prevalence of Opioid Use Disorder for Pregnant Women (Webinar)


Treatment of Opioid Use Disorder in Pregnant Women (Webinar)

Buprenorphine Treatment for Pregnant Women with OUD (Webinar)


Issues Pertaining to Both Buprenorphine and Methadone (Webinar)

Neonatal Considerations During the Treatment of OUD (Webinar)

Section 6: Special Topics

  1. Co-occurring Conditions

ModuleTopicSubtopicTool or Resource

Module 6 

Special Topics

Co-occurring Physical, Behavioral, and Psychiatric Health Conditions

General Overview

Strategies to Address Opioid Use Disorder and Co-Occurring Behavioral Health Disorders (Webinar Part 1)

Anxiety/Depression and OUD

Clinical Presentation of Anxiety Disorders and Substance Use Disorder (Webinar)

Prevalence and Etiologies of Anxiety Disorder and OUD (Webinar)

Treatment Modalities and Management of Anxiety and OUD (Webinar)

Mood Disorders and OUD

Prevalence and Etiologies of Mood Disorders and OUD (Webinar)

Treatment Modalities and Management of Mood Disorders and OUD (Webinar)

Continuing Substance Use Disorder Treatment During COVID-19 

Provider Guidelines Substance Use Disorder Treatment Response During COVID-19: Guidelines for Continuation of Care (Document)

Section 7: Duration of MAT

  1. Discontinuing Medication-Assisted Treatment and Tapering Medications

ModuleTopicSubtopicTool or Resource

Module 7 

Duration of MAT

Discontinuing Medication-Assisted Treatment and Tapering Medications

Discontinuing Medication-Assisted Treatment and Tapering Medications

Guidelines for Changing Medication (Webinar)

Strategies for Retaining Patients in Treatment (Webinar)

Treatment Expectations and Treatment Retention Literature Review (Webinar)

Buprenorphine Tapering and Discontinuation Case Studies (Webinar)

How to Withdraw Patients from Opioids (Slides)

Last modified: Friday, April 10, 2020, 4:09 PM